Traws Pharma Inc (TRAW) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -12.69. The fair price of Traws Pharma Inc (TRAW) is between +Inf to +Inf according to relative valuation method. Compared to the current price of 1.67 USD , Traws Pharma Inc By Undervalued By Fair.

Relative Value

Fair Zone

+Inf-+Inf

Current Price：1.67

Fair

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Traws Pharma Inc (TRAW) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Traws Pharma Inc (TRAW) has a current Price-to-Book (P/B) ratio of 2.09. Compared to its 3-year average P/B ratio of 0.02, the current P/B ratio is approximately 8576.89% higher. Relative to its 5-year average P/B ratio of 1.15, the current P/B ratio is about 81.96% higher. Traws Pharma Inc (TRAW) has a Forward Free Cash Flow (FCF) yield of approximately -183.17%. Compared to its 3-year average FCF yield of -169.00%, the current FCF yield is approximately 8.39% lower. Relative to its 5-year average FCF yield of -120.60%, the current FCF yield is about 51.88% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for TRAW competitors is 5.16, providing a benchmark for relative valuation. Traws Pharma Inc Corp (TRAW.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of TRAW increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of TRAW in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is TRAW currently overvalued or undervalued?

What is Traws Pharma Inc (TRAW) fair value?

TRAW's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Traws Pharma Inc (TRAW) is between +Inf to +Inf according to relative valuation method.

How does TRAW's valuation metrics compare to the industry average?

The average P/S ratio for TRAW's competitors is 5.16, providing a benchmark for relative valuation. Traws Pharma Inc Corp (TRAW) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

What is the current P/B ratio for Traws Pharma Inc (TRAW) as of Mar 02 2026?

As of Mar 02 2026, Traws Pharma Inc (TRAW) has a P/B ratio of 2.09. This indicates that the market values TRAW at 2.09 times its book value.

What is the current FCF Yield for Traws Pharma Inc (TRAW) as of Mar 02 2026?

As of Mar 02 2026, Traws Pharma Inc (TRAW) has a FCF Yield of -183.17%. This means that for every dollar of Traws Pharma Inc's market capitalization, the company generates -183.17 cents in free cash flow.

What is the current Forward P/E ratio for Traws Pharma Inc (TRAW) as of Mar 02 2026?

As of Mar 02 2026, Traws Pharma Inc (TRAW) has a Forward P/E ratio of -0.77. This means the market is willing to pay $-0.77 for every dollar of Traws Pharma Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Traws Pharma Inc (TRAW) as of Mar 02 2026?

As of Mar 02 2026, Traws Pharma Inc (TRAW) has a Forward P/S ratio of 0.00. This means the market is valuing TRAW at $0.00 for every dollar of expected revenue over the next 12 months.

TRAW Valuation